Problem

Smoking addiction is the leading cause of preventable death and disease in the world, killing over 8 million people every year. If we don't put on our thinking caps and develop a solution, smoking will kill over 1 billion people in the 21st century alone. The good news is that over 55% of smokers try to quit every year. The bad news is that today's therapeutics have failure rates of around 90%, which means that quitting is nearly impossible and smokers can't escape their deadly cycle of addiction. 

Solution

At MIIST we're developing a novel therapeutic that is based upon the best-in-class science to make quitting easy. We've invented a proprietary smart inhaler through which we can deliver an FDA approved smoking cessation medication with superior pharmacokinetic performance as well as personalize the treatment to every patient to maximize efficacy at the individual level. 

Marketing

MIIST Therapeutics is tackling the $14B US smoking cessation market, which is forecasted to grow at a CAGR of 14.37% through 2027. This growth is supported by an increase in smoking cessation programs and consumer education regarding the dangers of smoking. The US is the largest geographical market by revenue, home to 34.1 million cigarette smokers and 11.7 million e-cigarette users, 70% of which are seeking to quit according to the CDC. 

The US market opportunity is to provide an effective smoking cessation product for the approximately 19 million smokers who try to quit every year, while reducing the mortality and economic burden associated with smoking. MIIST Therapeutics is developing this product as an FDA approved prescription treatment for smoking addiction.